EUVIMEDOpdag EUVIMED
Open access · CC BY 4.0

A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma

Tingting Kong, Ximo Xu iD, Xiao Zhang, Chuntao Wu, Zhengjun Qiu, Beiyuan Hu, Zihao Qi, Qiang Tian, Yuqin Yang, Hanguang Dong, Fei Wu, Tuo Jin and 2 more

Advanced Science · 2026

DOI: 10.1002/advs.76478 ↗

At a glance

Journal article in Advanced Science, 2026. Written by Tingting Kong and 13 co-authors. Institution: Department of Pancreatic Surgery, Shanghai Key Laboratory of Pancreatic Disease, Shanghai General Hospital, Shanghai Jiao Tong University School of M…. Major MEDLINE topics: Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Immunotherapy. 60 references. The full text is freely available (open access, CC BY 4.0). Funded by: National Natural Science Foundation of China, National Key Research and Development Program of China, Shanghai Sailing Program.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Pancreatic ductal adenocarcinoma (PDAC), a lethal malignancy with a 5‐year survival of 13%, faces limited therapeutic efficacy due to fibrotic barriers that block drug access to the therapeutic site, systemic toxicity of conventional chemotherapy, and an immunosuppressive tumor microenvironment (TME). Therapeutic agents with different functions, including FOLFIRINOX (FFX), surufatinib (SUR), and anti‐PD‐1 (αPD‐1), are co‐administered to tumors in animal models using microneedle (MN) patches to achieve site‐targeted synergistic efficacy. The core–shell MN structure is used, with the outer layer providing rapid FFX delivery and the inner layer providing sustained release of SUR and αPD‐1. Compared with intratumoral drug injection and traditional systemic administration, MN patch‐mediated administration markedly suppresses tumor growth and liver metastasis at lower doses, reduces systemic drug exposure and toxicity, and prolongs intratumoral drug retention. In addition, the MN patch‐mediated intratumoral co‐delivery reshapes the TME by boosting CD8 + T cells infiltration, inhibiting Foxp3 + regulatory T cells, and reducing CD206 + tumor‐associated macrophages infiltration, resulting in downregulation of tumor epithelial‐mesenchymal transition and increased tumor cell apoptosis. In summary, MN patch‐mediated delivery of therapeutic agents provides sufficient intratumoral doses and minimizes systemic toxicity through multiple microchannels, suggesting that MN patch co‐delivery is a promising adjunct for enhancing efficacy against PDAC.

Subjects

MeSH terms (MEDLINE)

Antineoplastic Combined Chemotherapy ProtocolsCarcinoma, Pancreatic DuctalPancreatic NeoplasmsImmunotherapyImmune Checkpoint InhibitorsAnimalsMicroneedle Drug DeliveryHumansMiceIrinotecanOxaliplatinLeucovorinFluorouracilFemaleTumor MicroenvironmentProgrammed Cell Death 1 Receptor

Author keywords

chemo‐immunotherapy strategylocalized drug deliverymicroneedlepancreatic ductal adenocarcinomatumor microenvironment

Substances

folfirinoxIrinotecanOxaliplatinLeucovorinFluorouracilProgrammed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Authors and institutions

  • Department of Pancreatic Surgery, Shanghai Key Laboratory of Pancreatic Disease, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Gastroenterology, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Department of Laboratory Animal Center, Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
  • Shanghai Institute of Hematology, State Key Laboratory of Medical Genomics, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine…
  • School of Pharmacy, Shanghai Jiao Tong University, Shanghai, China.

ORCID profiles: Ximo Xu, Yan Zheng

Funding

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Shanghai Sailing Program

Cite

APA

Kong, T., Xu, X., Zhang, X., Wu, C., Qiu, Z., Hu, B., Qi, Z., Tian, Q., Yang, Y., Dong, H., Wu, F., Jin, T., Zheng, Y., & Long, J. (2026). A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma. Advanced Science. https://doi.org/10.1002/advs.76478

Vancouver

Kong T, Xu X, Zhang X, Wu C, Qiu Z, Hu B, et al. A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma. Advanced Science. 2026. doi:10.1002/advs.76478

BibTeX
@article{Kong2026,
  author = {Kong, Tingting and Xu, Ximo and Zhang, Xiao and Wu, Chuntao and Qiu, Zhengjun and Hu, Beiyuan and Qi, Zihao and Tian, Qiang and Yang, Yuqin and Dong, Hanguang and Wu, Fei and Jin, Tuo and Zheng, Yan and Long, Jiang},
  title = {A Spatially Directed Microneedle Patch Enables Intratumoral Co‐Delivery of FOLFIRINOX, Surufatinib, and Anti‐PD‐1 for Chemo‐Immunotherapy of Pancreatic Ductal Adenocarcinoma},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.76478}
}
Start for free →